Sanofi ‘Strongly Disagrees’ With EMA Rejection Of NAS Status For Nexviadyme

 
• By Neena Brizmohun

Sanofi argues that the European Medicines Agency applies a narrow interpretation of its new active substance principles which is not appropriate for biological therapies, and that the regulator fails to consider the challenges of conducting clinical research in rare diseases.

Doctors and medical researchers on conference meeting, discussing possible solutions for resolving a world health crisis.
Sanofi says the CHMP's rejection of NAS status fails to recognize and reward innovation • Source: Alamy

More from Europe

More from Geography